Literature DB >> 3883177

Successful parenteral penicillin therapy of established Lyme arthritis.

A C Steere, J Green, R T Schoen, E Taylor, G J Hutchinson, D W Rahn, S E Malawista.   

Abstract

In a double-blind placebo-controlled trial carried out from 1980 to 1982, 20 patients with established Lyme arthritis were assigned treatment with 2.4 million U of intramuscular benzathine penicillin weekly for three weeks (total, 7.2 million U) and 20 patients received saline. Seven of the 20 penicillin-treated patients (35 per cent) had complete resolution of arthritis soon after the injections and have remained well during a mean follow-up period of 33 months. In contrast, all 20 patients given placebo continued to have attacks of arthritis (P less than 0.02). In 1983, of 20 patients treated with intravenous penicillin G, 20 million U a day for 10 days, 11 (55 per cent) had complete resolution of arthritis and have remained well since. As compared with nonresponders, penicillin-responsive patients in both studies were more likely to have previously received antibiotics for erythema chronicum migrans (P less than 0.02) and less likely to have been given intraarticular corticosteroids during or at the conclusion of parenteral therapy (P less than 0.1). The Lyme spirochete was not cultured from synovium or joint fluid. We conclude that established Lyme arthritis can often be treated successfully with parenteral penicillin. However, neither of the regimens that we tested is uniformly effective, and further experience will be needed to determine the optimal course of therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883177     DOI: 10.1056/NEJM198504043121401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

1.  Long term treatment of chronic Lyme arthritis with benzathine penicillin.

Authors:  M A Cimmino; S Accardo
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

Review 2.  Infection and infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

Review 3.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

Review 4.  Lyme disease in paediatrics.

Authors:  B Cryan; D J Wright
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

Review 5.  Lyme disease.

Authors:  D W Rahn; S E Malawista
Journal:  West J Med       Date:  1991-06

6.  Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis.

Authors:  Kathryn L Jones; Gail A McHugh; Lisa J Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2009-07

7.  In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.

Authors:  R Baradaran-Dilmaghani; G Stanek
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 8.  Treatment of Lyme arthritis.

Authors:  M A Cimmino; G L Moggiana; M Parisi; S Accardo
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

9.  Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.

Authors:  J E Craft; D K Fischer; G T Shimamoto; A C Steere
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

10.  Persistent atrioventricular block in Lyme borreliosis.

Authors:  W Mayer; F X Kleber; B Wilske; V Preac-Mursic; W Maciejewski; H Sigl; E Holzer; W Doering
Journal:  Klin Wochenschr       Date:  1990-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.